Why the study?
Oral treprostinil titration can be prolonged, whereas prior parenteral treprostinil allows attainment of higher doses, prompting evaluation of rapid parenteral induction to quickly achieve higher oral doses in pulmonary arterial hypertension.
Does parenteral treprostinil induction increase the percentage of patients reaching ≥12 mg daily of oral treprostinil at Week 16 in prostacyclin-naïve patients with pulmonary arterial hypertension?
Does parenteral treprostinil induction increase the percentage of patients reaching ≥12 mg daily of oral treprostinil at Week 16 in prostacyclin-naïve patients with pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Short-course parenteral treprostinil induction enables rapid attainment of high-dose oral treprostinil and improves clinical parameters in prostacyclin-naïve patients with pulmonary arterial hypertension.
RATIONALE: Oral treprostinil slows disease progression and improves exercise capacity in pulmonary arterial hypertension; however, titration can be prolonged. Published data suggests prostacyclin-naïve patients achieve total daily oral treprostinil doses of about 6 mg by Week 16, while those on prior parenteral treprostinil reach higher doses at the same timepoint. OBJECTIVES: EXPEDITE (NCT03497689), a single-arm, multicenter study, assessed the efficacy of rapid parenteral treprostinil induction to quickly reach higher doses of oral treprostinil for the treatment of pulmonary arterial hypertension. METHODS: Parenteral treprostinil was titrated for 2-8 weeks, followed by cross-titration of oral treprostinil. The primary endpoint was percentage of patients reaching ≥12 mg daily of oral treprostinil at Week 16. Secondary endpoints included clinical changes from baseline to Week 16. RESULTS: Twenty-nine prostacyclin-naïve patients were included in efficacy analyses. At Week 16, the mean daily oral treprostinil dose was 16.4 mg; 79% of patients met the primary endpoint. From baseline to Week 16, median REVEAL Lite 2 score improved (decreased) from 6 to 3.5 (p = 0.0006). Statistically significant improvements were also seen in World Health Organization Functional Class, N-terminal-pro brain natriuretic peptide levels, 6-minute walk distance, right atrial area, Borg Dyspnea Score, and emPHasis-10 score. Favorable trends were seen in risk stratification, echocardiography parameters, disease symptoms, and treatment satisfaction. CONCLUSION: Short-course parenteral treprostinil induction resulted in oral treprostinil doses over twice those reported in de novo initiations and may be a useful approach to quickly achieve the therapeutic benefits of oral treprostinil.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: